Search Results - "Quadrini, S"

Baseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: An Italian melanoma intergroup study by Marconcini, R., Tanda, E., Di Guardo, L.A., Nigro, O., Fava, P., Todisco, A., Morgese, F., Cortellini, A., Stroppa, E., Gallizzi, G., Festino, L., Grego, E., Quadrini, S., Orlandini, C., Nuzzo, A., Manacorda, S., Bloise, F., Indini, A., Astrua, C., Falcone, A.

Get full text

1950 Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study by Gamucci, T, Mentuccia, L, Vici, P, Iezzi, L, Sperduti, I, Astone, A, Marchetti, P, Pizzuti, L, Michelotti, A, Sini, V, Cassano, A, Ciancola, F, Quadrini, S, Moscetti, L, Landucci, E, Sergi, D, Magnolfi, E, Natoli, C

Get full text

2544 Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety by Fabbri, M.A, Cortesi, E, Marchetti, P, Santini, D, Gamucci, T, Angelini, F, Longo, F, Milano, A, Mancini, M.L, Giuli, A, Quadrini, S, Sperduti, I, Pellegrino, A, Ratta, R, Primi, F, Chilelli, M.G, Ruggeri, E.M

Get full text

4023 POSTER First-line Oral Vinorelbine for Elderly or Unfit Patients With Advanced/metastatic Non-small Cell Lung Cancer by Mansueto, G, Longo, F, Stumbo, L, De Filippis, L, Del Signore, E, Quadrini, S, Del Bene, G, Adua, D, Lapadula, V, Di Seri, M

Get full text

3065 POSTER Palonosetron, Aprepitant and Dexamethasone to Prevent Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy in Lung Cancer Patients by Longo, F, Mansueto, G, Lapadula, V, Del Bene, G, De Filippis, L, Gamucci, T, Stumbo, L, De Sanctis, R, Quadrini, S, Di Seri, M

Get full text

Safety and Efficacy of Oral Vinorelbine and Capecitabine Combination for Metastatic Breast Cancer by Di Seri, M., De Sanctis, R., Quadrini, S., Adua, D., Stumbo, L., Del Signore, E., Gori, B., Grassi, P., Basile, M.L., Longo, F.

“…The aim of this prospective open-label study was to evaluate the efficacy and safety of oral vinorelbine in combination with capecitabine in patients with…”
Get full text

2124P The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study by Muscaritoli, M., Modena, A., Valerio, M., Marchetti, P., Magarotto, R., Quadrini, S., Narducci, F., Tonini, G., Grassani, T., Cavanna, L., Di Nunzio, C., Citterio, C., Occelli, M., Strippoli, A., Chiurazzi, B., Frassoldati, A., Altavilla, G., Lucenti, A., Nicolis, F., Gori, S.

Get full text

3072 Palonosetron plus a three-day aprepitant and dexamethasone schedule to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy by Mansueto, G, Longo, F, De Sanctis, R, Lapadula, V, Quadrini, S, D'Antoni, I, Grande, R, Cortesi, E, Gamucci, T, DiSeri, M

Get full text

9083 Oral vinorelbine in elderly or unfit patients with metastatic NSCLC by Stumbo, L, Gori, B, Signore, E. Del, Quadrini, S, De Sanctis, R, De Filippis, L, Frantellizzi, V, D'Antoni, I, Longo, F, DiSeri, M

Get full text

9156 Safe and long-lasting tumour control with erlotinib in advanced non-small cell lung cancer by Quadrini, S, De Sanctis, R, Gori, B, Del Signore, E, Stumbo, L, Sollami, R, Frantellizzi, V, Grassi, P, DiSeri, M, Longo, F

Get full text

2121 Colorectal cancer liver metastases treated with target therapies: monitoring response with contrast-enhanced ultrasonography (CE-US) by De Sanctis, R, Quadrini, S, Stumbo, G, Gori, B, Del Signore, E, Adua, D, Recine, F, De Filippis, L, Longo, F, DiSeri, M

Get full text

Observational prospective study to evaluate survival, quality of life and cost of oncologic treatments for advanced non small cell lung cancer (NSCLC) patients that progressed after a first line of treatment: preliminary analysis by Quadrini, S., Sperduti, I., Narducci, F., Ciancola, F., Mastroianni, D., Mauri, M., Fabbri, A., Ruggieri, E.M., Roma, C.L., Mansueto, G., Gamucci, T.

Get full text

1258PBaseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: An Italian melanoma intergroup study by Marconcini, R, Tanda, E, Di Guardo, L A, Nigro, O, Fava, P, Todisco, A, Morgese, F, Cortellini, A, Stroppa, E, Gallizzi, G, Festino, L, Grego, E, Quadrini, S, Orlandini, C, Nuzzo, A, Manacorda, S, Bloise, F, Indini, A, Astrua, C, Falcone, A

Get full text

Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy by Grossi, F., Crinò, L., Misino, A., Bidoli, P., Delmonte, A., Gelsomino, F., Proto, C., Mancini, M., Landi, L., Turci, D., Quadrini, S., Antonelli, P., Marchetti, P., Toschi, L., Giusti, S., Di Costanzo, F., Rastelli, F., Sandri, P., Scotti, V., de Marinis, F.

Get full text

Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: a restrospective multicenter observational study by Iezzi, L., Mentuccia, L., Vici, P., Natoli, C., Sperduti, I., Astone, A., Marchetti, P., Pizzuti, L., Michelotti, A., Sini, V., Cassano, A., Ciancola, F., Quadrini, S., Moscetti, L., Landucci, E., Magnolfi, E., Sergi, D., Gamucci, T.

Get full text

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life” by Fabbri, M.A., Santini, D., Cortesi, E., Gamucci, T., Marchetti, P., Longo, F., Angelini, F., Sperduti, I., Milano, A., Pellegrino, A., Nelli, F., Primi, F., Raffaele, R., Mancini, M.L., Quadrini, S., Giuli, A., Ruggeri, E.M.

Get full text

Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population by Crinò, L., Bidoli, P., Delmonte, A., Grossi, F., de Marinis, F., Sperandi, F., Piantedosi, F., Vitali, M., Soto Parra, H., Scagnoli, S., Minuti, G., Calabrò, L., Tiseo, M., Turci, D., Quadrini, S., Antonelli, P., Manzo, A., Prediletto, I., Giannarelli, D., Galetta, D.

Get full text

Fact- B and Esas in Metastatic Breast Cancer (Mbc) Patients (Pts) Treated with Eribulin: Results of a Multicenter Prospective Observational Study by Mentuccia, L., Vici, P., Sperduti, I., Pizzuti, L., Moscetti, L., Vaccaro, A., Quadrini, S., Magnolfi, E., Fabbri, M.A., Zampa, G., Giampaolo, M.A., Sergi, D., Narducci, F., Sacca, M. Maugeri, Gamucci, T.

Get full text

1340PFACT- B AND ESAS IN METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) TREATED WITH ERIBULIN: RESULTS OF A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY by Mentuccia, L., Vici, P., Sperduti, I., Pizzuti, L., Moscetti, L., Vaccaro, A., Quadrini, S., Magnolfi, E., Fabbri, M.A., Zampa, G., Giampaolo, M.A., Sergi, D., Narducci, F., Sacca, M. Maugeri, Gamucci, T.

“…Abstract Aim: Eribulin (E) is a non taxane microtubule inhibitor indicated for treatment of MBC. To evaluate its tolerability, impact on Quality of Life (QoL)…”
Get full text

WALT trial (Phase I-II): Weekly non-pegylated liposomal anthracycline and taxane combination in first-line breast cancer chemotherapy by Rosati, M. S., Raimondi, C., Quadrini, S., De Sanctis, R., Stumbo, L., Gori, B., Del Signore, E., Poleggi, M. P., Di Seri, M.

“…Abstract only…”
Get full text